{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-046010","form_type":"8-K","ticker":null,"cik":"0000811240","company_name":"BIOLASE, INC","filed_at":"2024-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.037741+00:00","generated_at":"2026-06-03T17:40:26.923510+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BIOLASE receives Nasdaq delisting notice for bid price non-compliance; hearing requested","bullets":["Received Nasdaq Staff Letter on April 15, 2024, for failing $1.00 minimum bid price for 30 consecutive business days through March 1, 2024.","Ineligible for automatic compliance period due to prior panel monitor (Aug 14, 2023) and reverse stock splits exceeding 250:1 cumulative over two years.","Company will request a hearing before Nasdaq Hearings Panel; request automatically stays suspension/delisting pending hearing and panel decision.","Panel may grant extension of compliance period up to October 14, 2024. Prior letter of March 4, 2024 was issued in error."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-046010","json":"https://secwatch.observer/filing/0000950170-24-046010.json","markdown":"https://secwatch.observer/filing/0000950170-24-046010.md","text":"https://secwatch.observer/filing/0000950170-24-046010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811240/000095017024046010/0000950170-24-046010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811240/000095017024046010/biol-20240419.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T17:40:26.923510+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6742b5251aeb50a877186d0b8747778dbadf537d","claim":"BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"April 15, 2024, BIOLASE, Inc. (the “Company”) received a staff determination letter (the “Staff Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC notifying the Company that, unless the Company timely requests a hearing before a Nasdaq Hearings Panel (the “Panel”), its securities could be subject to suspension from trading on The Nasdaq Capital Market for failure to meet the $1.00 minimum closing bid price requirement for the 30 consecutive business days from January 19 through March 1, 2024, as required by Listing Rule 5550(a)(2), and that the Com","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/811240/000095017024046010/0000950170-24-046010-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}